Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers

MF Pichon, P Broet, H Magdelenat, JC Delarue, F Spyratos, JP Basuyau, S Saez, A Rallet, P Courrier, R Millon and B Asselain

Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris Cedex 13, France.

Summary The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 309 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radioligand assay according to a uniform protocol. A total of 68.8% of the tumours were ER positive and 54.0% PR positive (>20 fmol mg⁻¹ cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P<0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P<0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P<0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision.

Keywords: steroid receptors; breast cancer; prognosis

The majority of the studies on steroid receptors and prognosis of early breast cancer have found a positive correlation between the receptor status and patients' outcome. Several lines of data suggest that the expression of oestrogen and progesterone receptors in the primary tumour is related to the degree of differentiation of the tumour and its proliferation rate. The prognostic value of steroid receptors is probably linked to this relationship. Nevertheless, many discrepant results have been published relating to the actual prognostic value of steroid receptors. Several reports show that, with increasing follow-up, the initial advantage of positive receptor assays in terms of disease-free interval and survival vanishes (review in Raemaekers et al., 1985).

To address this question we set up a multicentric study of patients diagnosed and treated for primary breast cancer from the beginning of the 1970s. None of the patients had received adjuvant therapy, and receptor assays were all performed using radioligand techniques according to French national protocol (Martin et al., 1981).

Patients and methods

Patients

The 2257 patients were diagnosed and treated between the beginning of 1974 and the end of 1984 at eight different cancer centres, and the results of their follow-up were studied up to September 1993. The median follow-up time was 8.5 years. At 5 years 7.7% of the patients were lost to follow-up. Bilateral cancers and patients with any kind of adjuvant therapy were excluded from the study.

Information was recorded for each patient including age and hormonal status at diagnosis, clinical stage, histological classification and grade, pathological size and axillary lymph nodes status, steroid receptor status, as well as primary treatment (Table I).

The mean age of the patients was 59 years (range 20–98 years) and 74 patients (3.3%) were under 35 years. Sixty-five per cent of the patients were post-menopausal (range between centres 14–44%). Significant differences (P<0.0001) in the mean ages (range 55–65 years) and in the proportion of menopausal patients (range 14–44%) were also observed between centres.

Staging of the disease was performed according to the UICC criteria (stage I, 33.3%; stage II, 57.1%; stage IIIa, 5.7% and 2.4% stage IIIb (Table I)). Significant differences (P<0.0001) in the proportions of the different stages were also observed between centres (range 13–55% for stage I and 44–68% for stage II). The primary treatment was tumorectomy (32.7%) or mastectomy with axillary dissection (67.3%), followed by radiotherapy for 49.4% of cases.

Complete follow-up histories of the patients were recorded. During the first year, the follow-up was conducted at 3 month intervals, then over the following 2 year period at 6 month intervals, and thereafter annually.

Methods

Histology Tumour size was recorded as the maximum diameter of the surgically removed tumour mass. Axillary lymph nodes status (mean number examined: 13) was assessed by histological examination for 2045 patients. Grading of the tumours was performed according to the Scarff, Bloom and Richardson method (SBR) (Bloom and Richardson, 1957).

Steroid receptors assays Cytosol oestrogen (ER) and progesterone (PR) receptors were measured by the dextrancoated charcoal assay with tritiated ligands (Martin et al., 1981). Before the development of a national quality control in 1981, subsequently linked to the EORTC (European Organization for Research and Treatment of Cancer) quality control, all participants used internal quality controls made.

Correspondence: M-F Pichon, Laboratoire d’Immunanalyse, Centre Rene Huguenin, 35 rue Dailly, 92210 Saint-Cloud, France

Received 21 July 1995; 7 November 1995; accepted 9 January 1996
Table 1 Population characteristics

| Characteristics                  | Number (%) of patients |
|----------------------------------|------------------------|
| Age                              |                        |
| Mean (years)                     | 59                     |
| Range (min, max)                 | 20–98                  |
| Hormonal status                  |                        |
| Premenopausal                    | 791 (35.0)             |
| Post-menopausal                  | 1466 (65.0)            |
| TNM stage                        |                        |
| I                                | 752 (33.3)             |
| II                               | 1290 (57.1)            |
| III                              | 130 (5.7)              |
| IIIb                             | 56 (2.4)               |
| ND                               | 29 (1.5)               |
| Tumour size (mm)                 |                        |
| <20                              | 964 (42.7)             |
| 20 to 50                         | 1038 (46.0)            |
| ≥50                              | 163 (7.2)              |
| ND                               | 92 (4.1)               |
| Histology                        |                        |
| Ductal                           | 1849 (82.0)            |
| Lobular                          | 105 (4.6)              |
| Other histology                  | 303 (13.4)             |
| Histological grade (SBR)         |                        |
| I                                | 466 (20.6)             |
| II                               | 1144 (50.7)            |
| III                              | 402 (17.8)             |
| ND                               | 245 (10.9)             |
| Axillary lymph nodes (pN)        |                        |
| None                             | 1511 (66.9)            |
| 1–3                              | 443 (19.6)             |
| ≥4                               | 91 (4.0)               |
| ND                               | 212 (9.5)              |
| ER                               |                        |
| Negative                         | 571 (25.3)             |
| Positive                         | 1554 (68.8)            |
| ND                               | 132 (5.9)              |
| PR                               |                        |
| Negative                         | 948 (42.0)             |
| Positive                         | 1218 (54.0)            |
| ND                               | 91 (4.0)               |

ND, not determined; ER, oestrogen receptors; PR, progesterone receptors. Positivity if ≥10 fmol mg⁻¹ cytosol protein.

The mean size of the tumours was 28.9 mm (range between centres 20.4–35.6 mm). A total of 1511 (66.9%) patients were node negative, 443 (19.6%) had 1–3 invaded nodes, 91 (4.0%) more than four invaded nodes (range between centres for node-negative patients 42–100%). Eighty-two per cent were ductal carcinomas, 4.6% were lobular carcinomas, the other particular histological types were recorded as a whole group (13.4%). In all 20.6% were SBR grade I (range between centres 14–53%), 50.7% were SBR grade II (range 21–70%), 17.8% were SBR grade III (range 9–36%) (Table I). Significant variations in the mean tumour size, proportions of positive or negative lymph nodes and in the three SBR groups were observed between different centres (P<0.001).

Some 68.8% of the tumours were ER positive (mean concentration 93 fmol mg⁻¹ cytosol protein), 54.0% were PR positive (mean concentration 73 fmol mg⁻¹ protein). For 223 cases only one receptor could be measured because of insufficient tumour tissue. Positivity for both receptors was observed in 53.3% of the tumours. 23.9% were all negative, 19.8% were only ER positive and 3.0% only PR positive. Table II summarises the results of receptor assays from the participating centres.

Receptor status and patients characteristics (Table III).

ER was significantly related to: age (P=0.005), menopausal status (P=0.005), lymph node involvement (P=0.03), tumour size (P=0.04), histological type of the tumour (P=0.0001) and SBR grade (P=0.001). PR was significantly related to clinical stage (P=0.001), lymph node involvement (P=0.015), tumour size (P=0.04), histological type (P=0.0001) and grade (P=0.001).

Patients’ outcome

At the end point of our study, we had recorded 307 local recurrences, 589 metastases and 673 deaths including 537 from cancer. The patients’ population also displayed 199 second cancers, including 105 cancers of the contralateral breast. Overall survival at 60 months was 83.8±1.5% and 67.2±1.9% at 120 months.

Univariate analysis of disease-free interval and of overall survival A total of 74.1±0.9% of the patients were free of...
Patients & steroid receptors and clinical or histological characteristics

| Patients | ER− n (%) | ER+ n (%) | P-value | PR− n (%) | PR+ n (%) | P-value |
|----------|-----------|-----------|---------|-----------|-----------|---------|
| Age (years) |           |           |         |           |           |         |
| <35      | 28 (42)   | 39 (58)   | 0.005   | 38 (53)   | 34 (47)   | 0.12    |
| ≥35      | 540 (26)  | 1506 (74) |          | 903 (43)  | 1179 (57) |          |
| Hormonal status |           |           |         |           |           |         |
| Premenopausal | 226 (31)  | 512 (69)  | 0.005   | 287 (37)  | 487 (63)  | 0.0001  |
| Post-menopausal | 343 (25)  | 1034 (71) |          | 655 (47)  | 728 (53)  |          |
| TNM stage |           |           |         |           |           |         |
| I        | 186 (26)  | 518 (74)  | 0.5     | 285 (39)  | 448 (61)  | 0.001   |
| II       | 324 (26)  | 906 (74)  | 0.04    | 561 (45)  | 677 (55)  | 0.036   |
| III      | 54 (20)   | 123 (70)  | 0.04    | 92 (52)   | 83 (48)   |          |
| Tumour size (mm) |           |           |         |           |           |         |
| <20      | 221 (24)  | 683 (76)  | 0.04    | 370 (40)  | 559 (60)  |          |
| 20–50    | 251 (36)  | 724 (74)  | 0.04    | 451 (45)  | 547 (55)  |          |
| ≥50      | 55 (34)   | 106 (66)  | 0.04    | 74 (46)   | 85 (54)   |          |
| Histology |           |           |         |           |           |         |
| Ductal   | 444 (25)  | 1310 (75) | 0.0001  | 731 (41)  | 1055 (59) | 0.0001  |
| Lobular  | 18 (19)   | 74 (81)   | 0.0001  | 44 (46)   | 51 (54)   |          |
| Other    | 107 (39)  | 168 (61)  | 0.0001  | 170 (60)  | 112 (40)  |          |
| Histological grade |           |           |         |           |           |         |
| SBR      |           |           |         |           |           |         |
| I        | 61 (14)   | 374 (86)  | 0.001   | 135 (30)  | 320 (70)  | 0.001   |
| II       | 236 (22)  | 843 (78)  | 0.001   | 425 (38)  | 682 (62)  |          |
| III      | 175 (46)  | 207 (54)  | 0.001   | 255 (65)  | 138 (35)  |          |
| Axillary lymph node (pN) |           |           |         |           |           |         |
| None     | 385 (27)  | 1057 (73) |          | 652 (44)  | 813 (56)  |          |
| 1–3      | 96 (23)   | 318 (77)  | 0.03    | 161 (39)  | 225 (61)  | 0.015   |
| ≥4       | 35 (36)   | 62 (64)   | 0.03    | 50 (54)   | 43 (46)   |          |

Table II Oestrogen and progesterone receptors according to the participating centres

| Centre | n | Median | Mean (s.e.m.) | ER+ (CI) | Median | Mean (s.e.m.) | PR+ (CI) |
|--------|---|--------|---------------|----------|--------|---------------|----------|
| 1      | 693 | 57.0   | 105.2 (5.7)   | 76 (76-82) | 17.0   | 81.0 (5.7)   | 59 (55-63) |
| 2      | 608 | 30.0   | 75.9 (5.1)    | 76 (73-79) | 16.0   | 49.1 (3.7)   | 65 (61-69) |
| 3      | 299 | 81.0   | 141.9 (9.5)   | 84 (80-88) | 44.0   | 95.5 (8.1)   | 59 (53-65) |
| 4      | 289 | 11.5   | 46.7 (6.6)    | 54 (48-60) | 7.0    | 19.7 (2.7)   | 38 (32-44) |
| 5      | 229 | 25.0   | 75.0 (8.5)    | 64 (58-70) | 11.0   | 124.2 (15.1) | 40 (34-46) |
| 6      | 47  | 48.0   | 110.7 (25.5)  | 75 (40-95) | 41.0   | 99.7 (24.3)  | 62 (26-88) |
| 7      | 64  | 34.0   | 176.1 (36.7)  | 70 (58-82) | 21.0   | 96.7 (23.9)  | 56 (44-68) |
| 8      | 28  | 12.5   | 71.6 (31.2)   | 46 (27-65) | 51.5   | 141.5 (34.8) | 57 (29-75) |

ER, oestrogen receptors; PR, progesterone receptors. Positivity if ≥10 fmol mg⁻¹ cytosol protein. CI, confidence interval at 95%; s.e.m., standard error of the mean.

Table III Correlation between steroid receptors and clinical or histological characteristics

Survival after the first metastasis

We also sought a potential predictive value of steroid receptors after a first metastasis. The univariate analysis shows that both ER and PR have a favourable influence upon survival after a first metastasis, the difference between positive and negative groups being significant at a level of P<0.0001 for each comparison (only the ER chart is presented; Figure 6). The median of overall survival after a first metastasis is 29 months for ER-

Figure 1 Overall survival by ER status (●, ER−; □, ER+). 1261/422 patients ER−/ER− at risk for 60 months, 482/164 patients ER+/ER− at risk for 120 months.
positive and 15 months for ER-negative tumours (RR = 2.0), and 33 and 16 months for PR-positive and negative tumours respectively (RR = 1.90).

Multivariate analysis The following variables were introduced in the Cox model: age, menopausal status, clinical stage, size of the tumour, node involvement, histological type and grade of the tumour and steroid receptors. We have chosen a cut-off of 35 years for the age groups, in accordance with the results of several studies (Adami et al., 1986; Host and Lund, 1986), showing that the differences in overall survival are at a maximum when using that cut-off. The influence of these factors on disease-free interval, occurrence of metastases and survival was evaluated in a forward stepwise regression. The results for the three models are presented in Table V. For each factor, the entry step number,

Figure 2 Overall survival by PR status (□: PR -; ○: PR +, 1017 680 patients PR - PR + at risk for 60 months, 351 285 patients PR + PR - at risk for 120 months.

Figure 3 Overall survival by combined ER and PR status (□: ER - PR -; ○: ER - PR +; △: ER + PR -; ×: ER + PR +, 922 340 311 51 patients ER - PR +/ER + PR -/ER + PR +/ER - PR - at risk for 60 months, 321 138 142 20 patients ER + PR +/ER - PR +/ER + PR +/ER + PR - at risk for 120 months.

Figure 4 Metastasis-free survival according to ER status (□: ER -; ○: ER +, 1213.369 ER - ER + at risk for 60 months, 436 155 patients ER - ER + at risk for 120 months.

Figure 5 Metastasis-free survival according to PR (□: PR -; ○: PR +, 911.634 PR +/PR - at risk for 60 months, 318.264 patients PR +/PR - at risk for 120 months.

| Table IV Five and 10 years' results |
|-------------------------------------|
|                                     |
| 5 years | 10 years | 5 years | 10 years | 5 years | 10 years |
| ER*     | ER -     | 75.9 (1.8) | 63.4 (2.2) | 72.1 (2.2) | 65.0 (2.2) | 66.2 (2.0) | 58.0 (2.2) |
| ER -    | 90.1 (0.8) | 75.8 (1.3) | 82.2 (1.0) | 73.3 (1.2) | 76.4 (1.1) | 65.8 (1.3) |
| PR*     | PR -     | 80.3 (1.3) | 66.7 (1.7) | 75.9 (1.4) | 67.6 (1.7) | 69.7 (1.5) | 60.6 (1.7) |
| PR +    | 91.5 (0.8) | 77.2 (1.4) | 82.9 (1.1) | 74.4 (1.4) | 77.3 (1.2) | 66.3 (1.5) |
| ER and PR** | ER + PR + | 91.4 (0.9) | 76.7 (1.5) | 82.4 (1.2) | 73.4 (1.5) | 77.1 (1.3) | 66.1 (1.6) |
| ER + PR + | 89.0 (4.0) | 75.6 (6.5) | 81.7 (5.0) | 75.9 (6.3) | 71.5 (3.9) | 66.0 (6.7) |
| ER + PR + | 87.2 (1.7) | 73.9 (2.5) | 82.0 (1.9) | 72.9 (2.4) | 75.1 (2.2) | 65.4 (2.6) |
| ER - PR - | 74.2 (2.0) | 61.6 (2.4) | 70.2 (2.1) | 63.0 (2.3) | 64.9 (2.2) | 55.8 (2.5) |

DF, Disease-free; ER, oestrogen receptors; PR, progesterone receptors. Positivity if ≥ 10 fmol mg⁻¹ cytosol protein. * All P-values less than 0.01 for the three criteria. ** All P-values less than 0.01 testing for heterogeneity and between the group ER + PR + and ER - PR -.
the relative risk and its confidence interval are displayed. The disease-free interval is reduced for patients under 35 years, for patients with positive nodes or large tumour size or high SBR grade and when the tumours are ER negative. PR status has no statistical significance regarding the disease-free interval.

The risk of developing metastases increases for patients under 35 years, for positive lymph nodes, for large tumour size, for high SBR grade and for ER-negative tumours. Again, PR status has no prognostic value in this context.

With regard to the mortality risk through breast cancer, the significant variables of the Cox model were: menopausal status, high clinical stage, large tumour size, positive lymph nodes, high SBR grade and ER negativity. PR status was found to be non-significant. No significant differences in the relative risks associated to the ER or PR status were found among premenopausal vs post-menopausal patients.

**Table V** Adjusted relative risks* with their 95% confidence interval (Cox model)

| Variable                            | Esm | Disease-free survival | Esm | Metastasis-free survival | Esm | Survival |
|-------------------------------------|-----|-----------------------|-----|--------------------------|-----|----------|
| Histological grading (SBR)          |     |                       |     |                          |     |          |
| I                                  | 1   | 1                     | 1   | 1                        | 1   | 1        |
| II                                 | 2.09 | (1.61-2.72)          | 2.32 | (1.69-3.18)          | 2.45 | (1.71-3.50) |
| III                                | 2.50 | (1.57-3.98)*         | 2.86 | (1.67-4.88)*         | 2.80 | (1.54-5.07)* |
| Axillary node status (pN)           | 2   |                       | 2   |                          | 2   |          |
| None                               | 1.56 | (1.28-1.89)          | 1.85 | (1.50-2.31)          | 1.65 | (1.30-2.08) |
| 1-3                                | 2.29 | (1.36-3.86)          | 2.99 | (1.77-5.17)          | 3.23 | (1.82-5.69) |
| >3                                 |     |                       |     |                          |     |          |
| Tumour size                         |     |                       |     |                          |     |          |
| <30 mm                              | 3   |                       | 3   |                          | 3   |          |
| 20-50 mm                            | 1.46 | (1.22-1.74)          | 1.56 | (1.27-1.97)          | 1.37 | (1.06-1.76) |
| >50 mm                              | 2.05 | (1.31-3.22)          | 2.06 | (1.26-3.38)*         | 1.90 | (1.07-3.34) |
| Age (years)                         | 4   |                       | 4   |                          | 4   |          |
| <35                                 |     |                       |     |                          |     |          |
| ≥35                                 | 2.78 | (1.91-4.03)          | 2.78 | (1.85-4.17)          | NS  |          |
| ER status                           | 5   |                       | 5   |                          | 4   |          |
| Positive                           |     |                       |     |                          |     |          |
| Negative                           | 1.35 | (1.13-1.61)          | 1.45 | (1.19-1.75)          | 1.85 | (1.55-1.95) |
| TNM stage                           |     |                       |     |                          |     |          |
| I                                  | NS  |                       | NS  |                          | 1   |          |
| II                                 |     |                       |     |                          |     |          |
| III                                | 1.38 | (1.05-1.82)          | 1.38 | (1.01-2.70)*         | 1.49 | (1.01-2.70)* |
| Hormonal status                    |     |                       |     |                          |     |          |
| Premenopausal                      |     |                       |     |                          |     |          |
| Post-menopausal                    | 1.27 | (1.02-1.58)          |     |                          |     |          |

* Relative risks are referred to the best prognosis group. Esm, entry step number. ER, oestrogen receptor; Positivity if ≥ 10 fmol mg⁻¹ cytosol protein. NS, not significant. *Not significant with the upper group.
Evolution of the relative risk associated to ER status with elapsed time As Figures 1 and 4 show a trend for the prognostic value of ER status to decrease with elapsed time, we have thus studied a model fitting this observation. For this purpose, we have introduced a dependence of time in the Cox model for the risk associated to ER status. This time-dependent model results in a better fitting of the data ($P<0.001$) than the proportional hazard model. Figures 7 and 8 represent the time-dependent evolution of the relative risks of developing metastases or of death according to ER status. The relative risk of death (4.68) for ER-negative tumours at diagnosis tends towards 1 after 8 years of follow-up. The relative risk of developing metastases linked to ER status decreases rapidly during the first 2 years.

Prognostic value of ER and PR in low-risk patients A total of 960 patients were older than 35 years with negative lymph nodes, a tumour size less than 50 mm and SBR grade I or II. The disease-free survival was shorter among patients with ER-negative tumours (RR = 1.34, $P = 0.02$). The metastases-free survival was also shorter for ER-negative tumours (RR = 1.37, $P = 0.02$). In both cases, PR status showed no prognostic value. The overall survival for these low-risk patients was found to be significantly different according to ER and PR status. The relative risks for ER-negative tumours was 1.62 ($P = 0.006$) and 1.36 ($P = 0.003$) for PR-negative tumours.

Discussion

The present report is a multicentric study, with inherent advantages and pitfalls. Among the advantages are the large number of patients included in the study, the extensive follow-up and the absence of intervening adjuvant therapies. Conversely, since the data rely essentially upon the earliest steroid receptor assays performed for breast cancer management, one might question whether they are biased by a selection of large tumours because of technical requirements. As expected, when compared with recent studies displaying the pathological sizes with the same cut-off, a difference is observed in the proportions of T1 and T2 or more tumours. Our series include a smaller proportion of small tumours and more tumours over 20 mm than the recent ones (Mathiesen et al., 1991; Stal et al., 1992). Nevertheless, the observed survival rate for metastases-free patients in our series is similar to the statistics of the Fédération Nationale des Centres de lutte contre le Cancer (72% at 5 years and 53% at 10 years; Enquete Permanente Cancer, 1991).

Significant differences appeared between variable means among the different participating centres. Some of them can be ascribed to regional differences in patient and medical behaviour relating to the early diagnosis and management of breast cancer. For example, the series from centre number 2 shows the youngest and thus the highest premoratalastic proportion of patients; the series from centre number 5 only includes node-negative patients since all the node-positive ones were discarded owing to adjuvant chemotherapy. Overall, it is conceivable that this heterogeneity may bring more statistical inferences than less dispersed series for the general population.

With regard to the data derived from laboratory work, two main points can lead to heterogeneous results: histological grading and receptor assays. Centre number 3 certainly shows the highest proportion of grade III tumours but this is caused by a preselection of tumours of bad prognosis at the very beginning of the study. The observed variability among the proportion of the three histological grades from the different centres remains within the limits previously described in a multicentric study of SBR grading (Jacquemier et al., 1981).

All steroid receptor assays were performed according to the same protocol, which was consequently published for the new groups intending to carry out the technique in their laboratories (Martin et al., 1981). However, the percentage of ER-positive tumours varies widely between centres, probably owing to differences in technical skills in the beginning of receptor assays. But, allowing for their relatively small number of patients and the fact that receptor results were treated as discontinuous variables (positive/negative) in the statistical analysis, we might consider that their relative weight has thus been reduced.

Our statistical analysis of the optimal cut-off to separate positive and negative subgroups led to a value of 8 fmol mg\(^{-1}\) cytosol protein for both receptors. For simplicity, we have preferred to keep the widely accepted cut-off of 10 fmol mg\(^{-1}\) cytosol protein. A search for a pejorative cut-off in the elevated concentrations of ER and PR showed no significant differences up to 1000 fmol mg\(^{-1}\) protein. Our series shows a better prognostic value for oestradiol receptor than for progesterone receptor in univariate analysis, in contrast with several previous studies (Thorpe et al., 1987; Gelbfish et al., 1988; Stal et al., 1992), but the differences between the relative performances of the two receptors remain small nevertheless.

Multivariate analysis of the prognostic value of steroid receptors has been performed in 11 previous studies selected for their long relative follow-ups and relatively large patients. Many of them addressed subgroups of patients, node-positive: Clark et al. (1993); node-negative: Thorpe et al. (1987), Silvestrini et al. (1995); patients under 50 years: Stal et al. (1992); infiltrating ductal carcinomas: Spyrou et al. (1989). Other studies presented results from unselected patients but with a mixed population receiving or not receiving systemic adjuvant therapy: Haybittle et al. (1982), Chevallier et al. (1988), Aaltomaa et al. (1991), Gelbfish et al. (1988), Mathiesen et al. (1991). Only the study by Todd et al. (1987), based on the former patient population of Haybittle, displays results from an important group of primary breast cancers without adjuvant therapy and with a relatively long follow-up, however PR was not studied. The criteria introduced into the Cox regression model also vary: all the studies include the clinical or pathological size of the tumour and the degree of invaded lymph nodes. But, for other classical prognostic parameters, such as histological grade, only 7/11 of the studies have included the SBR or a form of histological classification (nuclear pleomorphism, mitotic index); the other studies comprised adjuvant therapies or proliferation criteria such as ploidy, S-phase or tritiated thymidine incorporation. Moreover, the varying number of criteria in the different Cox models, from four (Aaltomaa et al., 1991) to ten (Chevallier et al., 1988), may explain the diverse conclusions obtained. But, it can be concluded that the Cox model, a majority (7/9) of the studies have concluded a better significance or a unique significance of PR and 3/11 showed a prognostic value for ER alone or for both receptors. It can be observed that the prognostic value of PR was particularly evidenced when the patients received adjuvant treatment.

The ER vanishing prognostic value, reaching a non-significant relative risk between negative and positive tumours during the follow-up, is difficult to explain. A similar trend was previously described by Spyrou et al. (1989) in a study of 1262 patients from the Centre René Huguenin. Two kinds of explanation can be proposed: either this reflects intrinsic biological properties of the cancer cells evolving towards hormone resistance, or it is caused by intervening therapies used to control metastatic spreading. The main conclusion from our study is that, by multivariate analysis, steroid receptor assays use a relatively limited predictive value when compared with the well-established prognostic criteria of early breast cancer. Steroid receptor assays in breast tumours represent the very first step of a general strategy to decipher the biological behaviour of human breast cancer for clinical purposes. An array of biological prognostic factors (proliferation markers, growth factors, proteases, oncogenes . . . ) has since been proposed. To this date, none of them has gained general
acceptance for clinical practice. Steroid receptor status, although an imperfect predictor of patients' outcome, still remains the only single biological parameter in use to suggest therapeutic directives for subgroups of breast cancer patients.

**References**

AALTIMA S, LIPPOHONEN P, ESKILINEN M, KOSMA VM, MARIN S, ALHAVA E AND SYRJANEN K. (1991). Hormone receptors as prognostic factors in female breast cancer. *Ann. Med.*, 23, 643–648.

ADAMI HO, MALKER B, HOLMBERG L, PERSONN I AND STONE B. (1986). The relation between survival and age at diagnosis in breast cancer. *N. Engl. J. Med.*, 315, 559–563.

BLOOM HJG AND RICHARDSON WW. (1957). Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed 15 years. *Br. J. Cancer*, 11, 359–377.

CHEVALLIER B, HEINZMANN F, MOSSERI V, DAUCE JP, BASTIT P, GRAIC Y, BRUNELLE P, BASUYAU JP, COMOZI M AND ASSELAIN B. (1988). Prognostic value of estrogen and progesterone receptors in operable breast cancer. *Cancer*, 62, 2517–2524.

CLARK GM, WENGER CR, BEARDSLEE S, OWENS MA, POUNDS G, OLDAKER T, VENDRELY P, PANDIAN MR, HARRINGTON D AND MCGUIRE WL. (1993). How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. *Cancer*, 71, 2157–2162.

COX DR. (1972). Regression models and life table (with discussion). *J. R. Stat. Soc. B*, 34, 187–202.

ENQUETE PERMANENTE CANCER 1975–1986. (1991). In *Monographie des Cancers du SE*, Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC), pp. 37. Doin: Paris.

GELBISH GA, DAVIDSON AL, KOPEL S, SCHREIBMAN B, GELBISH JS, DEGENSHEN GA, HERZ BL AND CUNNINGHAM JN. (1988). Relationship of estrogen and progesterone receptors to prognosis in breast cancer. *Ann. Surg.*, 207, 75–79.

HAYBITTLE JL, BLAMEY RW, ELSTON CW, JOHNSON J, DOYLE PJ, CAMPBELL FC, NICHOLSON RI AND GRIFFITHS K. (1982). A prognostic index in primary breast cancer. *Br. J. Cancer*, 45, 361–366.

HOST H AND LUND E. (1986). Age as a prognostic factor in breast cancer. *Cancer*, 57, 2217–2221.

JACQUEMIER J, VAGUE D, LIEUTAUD R, DE MASCAREL J, TROJANI M, MEUGE C, LE DOUSSAL V, GENTILE A, HEBERT H, KEMENY F, AMOURoux J AND CONTESSO G. (1981). Définition et reproductionsibilité du grading de Scarff et Bloom. In *Evaluation des Moyens de Diagnostic du Cancer du Sein*, Gerv. (ed.) pp. 173–185. JMT Conseil: Paris.

KALBFLEISH JD AND PRENTICE RL. (1980). The statistical analysis of failure time data. pp. 122–127. John Wiley and Sons: New York.